Nektar Therapeutics Income (Loss) from Equity Method Investments
Nektar Therapeutics (NKTR) reported Income (Loss) from Equity Method Investments of -$319.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-14
- Nektar Therapeutics income (loss) from equity method investments for the quarter ending 2026-06-30 was -$319.00K.
- Nektar Therapeutics income (loss) from equity method investments for the quarter ending 2026-03-31 was -$1.75M.
- Nektar Therapeutics income (loss) from equity method investments for the quarter ending 2025-12-31 was -$1.35M.
- Nektar Therapeutics income (loss) from equity method investments for the quarter ending 2025-09-30 was -$534.00K.
- Nektar Therapeutics income (loss) from equity method investments for fiscal 2025 was -$8.73M.
- Nektar Therapeutics income (loss) from equity method investments for fiscal 2024 was $0.00.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$319.00K 10-Q · filed 2026-08-14 | -$2.07M 10-Q · filed 2026-08-14 | -$3.42M derived: sum of 3 quarters · filed 2026-08-14 | -$3.95M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.75M 10-Q · filed 2026-05-08 | -$3.10M derived: sum of 2 quarters · filed 2026-05-08 | -$3.63M derived: sum of 3 quarters · filed 2026-05-08 | -$6.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$1.88M derived: sum of 2 quarters · filed 2026-03-13 | -$4.27M derived: sum of 3 quarters · filed 2026-08-14 | -$8.73M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$534.00K 10-Q · filed 2025-11-07 | -$2.92M derived: sum of 2 quarters · filed 2026-08-14 | -$7.38M 10-Q · filed 2025-11-07 | -$7.38M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$2.39M 10-Q · filed 2026-08-14 | -$6.85M 10-Q · filed 2026-08-14 | -$6.85M derived: sum of 3 quarters · filed 2026-08-14 | -$6.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$4.46M 10-Q · filed 2026-05-08 | -$4.46M derived: sum of 2 quarters · filed 2026-05-08 | -$4.46M derived: sum of 3 quarters · filed 2026-05-08 | -$4.46M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-13 | $0.00 10-K · filed 2026-03-13 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |